Crossmark

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s40001-023-01549-x

Published Online: 2024-01-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Glhoom, Shaymaa

Fergany, Aya

El-Araby, Dina

Abdelkhalek, Asmaa A.

Gomaa, Asmaa

Zayed, Eman O.

Abd-ElGwad, Mohamed
Funding

Funding for this research was provided by:

Tanta University
License Information

Text and Data Mining valid from 2024-01-05

Version of Record valid from 2024-01-05
More Information

Article History

Received: 7 October 2023

Accepted: 23 November 2023

First Online: 5 January 2024

Declarations

:

: Not applicable.

: Not applicable.

: There are no conflicts of interest.

Document is current

Any future updates will be listed below